Axoltis reports Phase 2 failure of experimental ALS drug but notes small signal

Axoltis Pharma, a French biotech, announced that its Phase 2 trial of an experimental ALS therapy did not meet its primary endpoints.

The company said the data were noisy but observed a modest trend that they believe justifies further development, and they plan to discuss next steps with regulators.

The outcome underscores the challenges of developing treatments for ALS and may affect the company's near term valuation, though the hinted signal could keep some investor interest alive.